Finding the next Prevail
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Freeline takes the haemophilia B gene therapy fight to Uniqure
Early data show that Freeline’s project can get factor IX levels into the normal range, but the group is still looking for the “Goldilocks” zone.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – hints of durability emerge for Uniqure's gene therapy
And bleeds seen with the “transformative” project were played down.
Ash 2020 preview – late-breaker puts Uniqure in pole position
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Is valrox dead?
Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.
No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
